Author

MD Stephen Keefe

Observed names: MD Stephen Keefe,, Stephen Keefe, Stephen M. Keefe, Stephen Michael Keefe

OpenAlex ID: A5111378094

Abstract CT088: [212Pb]VMT-a-NET in advanced SSTR2+ neuroendocrine tumors: safety and preliminary efficacy results from dose-finding cohorts 1,2 and 3

2026 · Thorvardur R. Halfdanarson, Richard L. Wahl, et al. · Cancer Research · 1

A phase I/IIa, first-in-human, multicenter, monotherapy and combination therapy with nivolumab dose-finding study of [ 212 Pb]VMT01 melanocortin-1-receptor–targeted, image-guided, alpha-particle therapy in subjects with previously treated unresectable or metastatic melanoma.

2026 · Zachary Scott Morris, Richard L. Wahl, et al. · Journal of Clinical Oncology

A phase I/IIa, image-guided, alpha-particle therapy study of [ 203 Pb]Pb-PSV359 and [ 212 Pb]Pb-PSV359 in patients with solid tumors that are known to be fibroblast activation protein (FAP)–positive.

2026 · Samuel Mehr, Ravi Patel, et al. · Journal of Clinical Oncology

Cohort-level safety and efficacy results for [ 212 Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)–expressing neuroendocrine tumors (NETs): Cohorts 1–3.

2026 · Thorvardur Ragnar Halfdanarson, Richard L. Wahl, et al. · Journal of Clinical Oncology

[212Pb]VMT-alpha-NET for advanced SSTR+ NETs: safety and preliminary efficacy results from cohorts 1 and 2 of the dose escalation phase

2026 · MD, Thorvardur Halfdanarson,, Richard Wahl, et al. · Endocrine Abstracts

Preliminary safety and efficacy data of [212Pb]VMT-[alpha]-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)

2025 · Wahl, MD Richard L, MD Lowell Anthony,, et al. · Endocrine Abstracts

Works count: 6

Citation count: 1

H-index: 1

I10-index: